“…Until recently, rAAVs produced limited retrograde transport (Aschauer et al, 2013;Castle et al, 2014;Hadaczek et al, 2016;Masamizu et al, 2011;McFarland et al, 2009;Salegio et al, 2013;Taymans et al, 2007;Towne et al, 2010). In NHP opto-and chemogenetics studies, AAVs primarily have been used to manipulate neural activity local to the injection site (Acker et al, 2016;Afraz et al, 2015;Cavanaugh et al, 2012;Dai et al, 2014;El-Shamayleh et al, 2017;Fetsch et al, 2018;Grayson et al, 2016;Ju et al, 2018;Klein et al, 2016;Lu et al, 2015;May et al, 2014;Nagai et al, 2016;Nakamichi et al, 2019;Stauffer et al, 2016;Tamura et al, 2017;Upright et al, 2018;Yazdan-Shahmorad et al, 2016). However, a new rAAV variant-rAAV2-retro-developed through in vivo directed evolution (Tervo et al, 2016) has gained recent popularity because of its highly efficient retrograde transport in rodents (Birdsong et al, 2019;Hong and Heo, 2020).…”